These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 34954641)

  • 1. Plumbagin reduction by thioredoxin reductase 1 possesses synergy effects with GLUT1 inhibitor on KEAP1-mutant NSCLC cells.
    Sun S; Zhang Y; Xu W; Yang R; Yang Y; Guo J; Ma Q; Ma K; Zhang J; Xu J
    Biomed Pharmacother; 2022 Feb; 146():112546. PubMed ID: 34954641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thioredoxin reductase 1 inhibitor shikonin promotes cell necroptosis via SecTRAPs generation and oxygen-coupled redox cycling.
    Zhang Y; Sun S; Xu W; Yang R; Yang Y; Guo J; Ma K; Xu J
    Free Radic Biol Med; 2022 Feb; 180():52-62. PubMed ID: 34973363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
    Torrente L; Prieto-Farigua N; Falzone A; Elkins CM; Boothman DA; Haura EB; DeNicola GM
    Redox Biol; 2020 Feb; 30():101440. PubMed ID: 32007910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thioredoxin reductase-1 levels are associated with NRF2 pathway activation and tumor recurrence in non-small cell lung cancer.
    Delgobo M; Gonçalves RM; Delazeri MA; Falchetti M; Zandoná A; Nascimento das Neves R; Almeida K; Fagundes AC; Gelain DP; Fracasso JI; Macêdo GB; Priori L; Bassani N; Bishop AJR; Forcelini CM; Moreira JCF; Zanotto-Filho A
    Free Radic Biol Med; 2021 Dec; 177():58-71. PubMed ID: 34673143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TrxR1 as a potent regulator of the Nrf2-Keap1 response system.
    Cebula M; Schmidt EE; Arnér ES
    Antioxid Redox Signal; 2015 Oct; 23(10):823-53. PubMed ID: 26058897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer.
    Dai B; Yoo SY; Bartholomeusz G; Graham RA; Majidi M; Yan S; Meng J; Ji L; Coombes K; Minna JD; Fang B; Roth JA
    Cancer Res; 2013 Sep; 73(17):5532-43. PubMed ID: 23824739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Details in the catalytic mechanism of mammalian thioredoxin reductase 1 revealed using point mutations and juglone-coupled enzyme activities.
    Xu J; Cheng Q; Arnér ES
    Free Radic Biol Med; 2016 May; 94():110-20. PubMed ID: 26898501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Selenoprotein thioredoxin reductase mediated menadione reduction: catalytic properties & inhibition effects].
    Zhang N; Sun S; Zhang Y; Yang Y; Zhang Y; Chen J; Xu W; Ma Q; Xu J
    Sheng Wu Gong Cheng Xue Bao; 2020 Oct; 36(10):2139-2150. PubMed ID: 33169578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inducing ubiquitination and degradation of TrxR1 protein by LW-216 promotes apoptosis in non-small cell lung cancer via triggering ROS production.
    Wang R; Zhong L; Wang T; Sun T; Yang J; Liu X; Wu Y; Guo Q; Gao Y; Zhao K
    Neoplasia; 2024 Jul; 53():101004. PubMed ID: 38733769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase.
    Peng X; Zhang MQ; Conserva F; Hosny G; Selivanova G; Bykov VJ; Arnér ES; Wiman KG
    Cell Death Dis; 2013 Oct; 4(10):e881. PubMed ID: 24157875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
    Leone A; Roca MS; Ciardiello C; Terranova-Barberio M; Vitagliano C; Ciliberto G; Mancini R; Di Gennaro E; Bruzzese F; Budillon A
    Free Radic Biol Med; 2015 Dec; 89():287-99. PubMed ID: 26409771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine.
    Anestål K; Arnér ES
    J Biol Chem; 2003 May; 278(18):15966-72. PubMed ID: 12574159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interplay between cytosolic disulfide reductase systems and the Nrf2/Keap1 pathway.
    Schmidt EE
    Biochem Soc Trans; 2015 Aug; 43(4):632-8. PubMed ID: 26551704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of thioredoxin reductase and glutathione reductase in plumbagin-induced, reactive oxygen species-mediated apoptosis in cancer cell lines.
    Hwang GH; Ryu JM; Jeon YJ; Choi J; Han HJ; Lee YM; Lee S; Bae JS; Jung JW; Chang W; Kim LK; Jee JG; Lee MY
    Eur J Pharmacol; 2015 Oct; 765():384-93. PubMed ID: 26341012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer.
    Vartanian S; Lee J; Klijn C; Gnad F; Bagniewska M; Schaefer G; Zhang D; Tan J; Watson SA; Liu L; Chen H; Liang Y; Watanabe C; Cuellar T; Kan D; Hartmaier RJ; Lau T; Costa MR; Martin SE; Merchant M; Haley B; Stokoe D
    Cancer Res; 2019 Oct; 79(19):4828-4839. PubMed ID: 31416841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethaselen: a potent mammalian thioredoxin reductase 1 inhibitor and novel organoselenium anticancer agent.
    Wang L; Yang Z; Fu J; Yin H; Xiong K; Tan Q; Jin H; Li J; Wang T; Tang W; Yin J; Cai G; Liu M; Kehr S; Becker K; Zeng H
    Free Radic Biol Med; 2012 Mar; 52(5):898-908. PubMed ID: 22210352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.
    Tian Y; Wu K; Liu Q; Han N; Zhang L; Chu Q; Chen Y
    J Hematol Oncol; 2016 Sep; 9(1):83. PubMed ID: 27601007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genistein mediates the selective radiosensitizing effect in NSCLC A549 cells via inhibiting methylation of the keap1 gene promoter region.
    Liu X; Sun C; Liu B; Jin X; Li P; Zheng X; Zhao T; Li F; Li Q
    Oncotarget; 2016 May; 7(19):27267-79. PubMed ID: 27029077
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Sitthideatphaiboon P; Galan-Cobo A; Negrao MV; Qu X; Poteete A; Zhang F; Liu DD; Lewis WE; Kemp HN; Lewis J; Rinsurongkawong W; Giri U; Lee JJ; Zhang J; Roth JA; Swisher S; Heymach JV
    Clin Cancer Res; 2021 Mar; 27(6):1720-1733. PubMed ID: 33323404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thioredoxin Reductase Inhibition for Cancer Therapy.
    Gencheva R; Arnér ESJ
    Annu Rev Pharmacol Toxicol; 2022 Jan; 62():177-196. PubMed ID: 34449246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.